Global Newsroom

CSL Reaffirms Commitment to Manufacture AstraZeneca COVID Vaccine into 2022

CSL Requires COVID-19 Vaccination for On-Site Employees and Visitors

$2.5 Million Funding Available to Australian Biomedical Researchers

New Patent Box policy will benefit domestic commercialisation of medical research

Onshore mRNA manufacturing will build Australian capability for next generation vaccine technologies

Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.

uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring.

Four Australian Research Programs to be Fast-Tracked in Partnership with CSL

Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19

CSL continues to provide medicines to patients around the world.

CSL is pleased to confirm that the final stages of manufacturing of the AstraZeneca COVID-19 vaccine for Australia are planned to commence next week, with first doses on track for release towards the end of March, subject to approval by the Therapeutic Goods Administration (TGA).

24 healthy volunteers to be recruited for study of plasma-derived COVID-19 Immunoglobulin

CSL Commences Manufacturing of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne.